ホーム › がん（全種類） › オハイオ › Cincinnati
Cincinnati、OHにおけるがん（全種類）の臨床試験
Cincinnatiとその周辺地域（約30マイル以内）の拠点で、がん（全種類）に関する27件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
被験者募集中第2相
- University of Cincinnati Medical Center. /ID# 278925, Cincinnati
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
被験者募集中第3相
- Oncology Hematology Care Clinical Trials, LLC, Fairfield · 15マイル先
Registry Study for Radiation Therapy Outcomes
被験者募集中観察研究
- University of Cincinnati Medical Center, Cincinnati
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
被験者募集中第3相
- Saint Elizabeth Medical Center Edgewood, Edgewood · 8マイル先
A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer
被験者募集中
- Cincinnati Children's Hospital Medical Center, Cincinnati
Pan Tumor Rollover Study
被験者募集中第2相
- Oncology Hematology Care, Cincinnati
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
被験者募集中第3相
- Oncology Hematology Care - Fairfield /ID# 280641, Fairfield · 15マイル先
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
被験者募集中第2相
- University of Cincinnati Medical Center, Cincinnati
- West Chester Hospital, West Chester · 15マイル先
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
被験者募集中第2/3相
- Oncology Hematology Care, Inc., Cincinnati
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
被験者募集中第3相
- Research Site, Edgewood · 8マイル先
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- USO - Oncology Hematology Care, Cincinnati
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
被験者募集中観察研究
- University of Cincinnati, Cincinnati
Project: Every Child for Younger Patients With Cancer
被験者募集中観察研究
- Cincinnati Children's Hospital Medical Center, Cincinnati
International Rare Brain Tumor Registry
被験者募集中観察研究
- Cincinnati Children's Hospital Medical Center, Cincinnati
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- TriHealth Cancer Institute-Westside, Cincinnati
- 他1件
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
被験者募集中第3相
- University of Cincinnati Physicians Group, LLC, Cincinnati
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
被験者募集中第1/2相
- Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- University Of Cincinnati Medical Center /ID# 251746, Cincinnati
Tempus Small Cell Lung Cancer Observational Study (Sculptor)
被験者募集中観察研究
- TriHealth Cancer Institute, Cincinnati
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
被験者募集中第1/2相
- University of Cincinnati, Cincinnati
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
被験者募集中第2相
- University of Cincinnati Medical Center, Cincinnati
GEMINI-NSCLC: NSCLC Biomarker Study
被験者募集中観察研究
- TriHealth Cancer Institute, Cincinnati
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Cincinnati
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
被験者募集中第1相
- The Christ Hospital Cancer Center, Cincinnati
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
被験者募集中観察研究
- University of Cincinnati Medical Center, Cincinnati
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
被験者募集中観察研究
- TriHealth Cancer Institute, Cincinnati
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
被験者募集中
- University of Cincinnati, Cincinnati
- West Chester Hospital (OH394), West Chester · 15マイル先
他の都市におけるがん（全種類）の試験
- Houston, TX121件の研究
- New York City, NY110件の研究
- Boston, MA86件の研究
- Los Angeles, CA73件の研究
- Nashville, TN65件の研究
- Philadelphia, PA59件の研究
- Durham, NC58件の研究
- Washington, DC58件の研究
- Chicago, IL51件の研究
- Seattle, WA49件の研究
- Atlanta, GA49件の研究
- Arlington, VA48件の研究
Cincinnatiにおける他の研究
- 非小細胞肺癌35件の研究
- 乳がん25件の研究
- 心不全24件の研究
- 大腸癌21件の研究
- 急性骨髄性白血病20件の研究
- 転移性癌20件の研究
- 卵巣がん19件の研究
- 肺がん19件の研究
- 肥満症19件の研究
- 前立腺がん18件の研究
- 多発性骨髄腫17件の研究
- 悪性黒色腫17件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。